SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Rheumatology and Clinical Immunology

[Return To Index page]
photo Mandy J McGeachy, PhD

Assistant Professor of Medicine

Email: mmcgeach@pitt.edu

Phone: 412-648-1587

Contact
Office: 3500 Terrace Street
BST South, S719
Pittsburgh, PA 15261
 
Phone: 412-648-1587
Fax: 412-383-8864
E-mail: mmcgeach@pitt.edu
Administrative Assistant:
Kim Reynolds
Email: kir4@pitt.edu
Phone: 412-648-9782
Education and Training
Education
BSc (Immunology), University of Glasgow, Scotland, UK, 2001
PhD (Immunology), University of Edinburgh, Scotland, UK, 2005
Training
Postdoc, Schering-Plough Biopharma/DNAX, 2009
Senior Scientist/Associate Principal Scientist, Merck Research Labs, 2011
Research Interest
The McGeachy lab studies mechanisms of activation and regulation of Th17 cells in autoimmune inflammation. In the past decade, Th17 cells have garnered much attention as drivers of tissue inflammation, and therapies to target Th17-associated pathways are making remarkable progress in clinic. Our research is uncovering unexpected roles for both immune and non-immune associated proteins in Th17 biology. For example, in one NIH-funded project we have identified that integrin avß3 is expressed by Th17 cells and is important for their ability to induce inflammation in EAE, the mouse model of multiple sclerosis. Ongoing studies are now investigating the mechanisms through which avß3 integrins regulate Th17 inflammation in different tissues of the body including LN. We are also studying inflammatory T cells in humans with rheumatoid arthritis, in a project recently funded by the Rheumatology Research Foundation to study effects of T cell costimulatory pathway blockade in RA. Biologic therapy in patients offers the opportunity to determine changes in T cells that are related to blockade of specific immune pathways, and we are collaborating with rheumatologists to conduct controlled longitudinal clinical studies to track changes in T cell populations that correspond blockade of TNF, CD28 or IL-6R. The University of Pittsburgh, including the McGeachy lab, is also one of five sites chosen nationally for the NIH/industry/foundation-funded Accelerating Medicines Partnership, which aims to dissect the immune networks that are active in different cellular populations isolated from RA joint tissues using state-of-the-art assays and bioinformatics.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Fang, D, Garg, AV, Kosar, K, Majumder, S, Kugler, DG, Mir, GH, Maggio, M, Henkel, M, Lacy-Hilbert, A, McGeachy, MJ. Inflammatory Th17 Cells Express Integrin avß3 for Pathogenic Function. Cell Reports. 2016.
Garg, A, Amatya, N, Chen, K, Cruz, JA, Grover, P, Whibley, N, Conti, HR, Hernandez Mir, G, Sirakova, T, Childs, EE, Smithgall, TE, Biswas, PS, Kolls, JK, McGeachy, MJ, Kollatukudy, PE, Gaffen, SL. MCPIP1 endoribonuclease activity negatively regulates interleukin-17-mediated signaling and inflammation. Immunity. 2015.
CJ Haines, Y Chen, WM Blumenschein, ..., MJ McGeachy. Autoimmune Th17 Memory Cell Function and Expansion are Dependent on IL-23. Cell Reports. 2013; 3(5): 1378-1388.
Y Chen, K Hochweller, C Haines, WB Blumenschein, T McClanahan, G Hamerling, DJ Cua, MJ McGeachy. Foxp3+ Regulatory T cells Promote Th17 Development in vivo. Immunity. 2011; 34(3): 409-421.
Sponsored Research/Activities
Title: Regulation of Th17 Functions in Autoimmune CNS Inflammation
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI110822
Start Year: 2014
End Year: 2019
Title: UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)
Role: Co-Investigator
Funding Agency: National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: UH2 AR067685
Start Year: 2014
End Year: 2017
Title: Regulation of Th17 Functions in Autoimmune CNS Inflammation
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R56 AI110822
Start Year: 2014
End Year: 2015
Title: IL-23 STAT3 Driven Oral Immune Responses to Candida Albicans
Role: Principal Investigator
Funding Agency: National Institute of Dental/Craniofacial Research
Grant Number: R01 DE023815
Start Year: 2013
End Year: 2018
Title: IL-17 Receptor Signaling in the Oral Mucosa (Administrative Supplement)
Role: Co-Investigator
Funding Agency: National Institute of Dental/Craniofacial Research
Grant Number: R01 DE022550
Start Year: 2013
End Year: 2017
Title: Identification of the PBMC Gene Signature that Predicts Requirement for Aggressive Therapy Such as Tofacitinib RA
Role: Principal Investigator
Funding Agency: Pfizer Inc.
Start Year: 2013
End Year: 2015
Title: A Novel Integrin Expressed by Th17 Cells in RA
Role: Principal Investigator
Funding Agency: Rheumatology Research Foundation
Start Year: 2013
End Year: 2014
Title: A Novel Receptor Expressed on Th17 Cells in Colitis
Role: Principal Investigator
Funding Agency: Samuel and Emma Winters Foundation
Start Year: 2012
End Year: 2013
Title: Rheumatoid Arthritis Comparative Effectiveness Research (RACER) Longitudinal Extension Study
Role: Co-Investigator
Funding Agency: Genentech, Inc.
Start Year: 2010
End Year: 2016
Notable Achievements
Member, American Association of Immunologists, 2011-present
Member, American College of Rheumatology, 2012-present
Member, International Cytokine and Interferon Society, 2013-present
International Cytokine and Interferon Society Young Investigator, 2013
Editorial Board Member, Cytokine, 2014-present
Editorial Board Member, Scientific Reports, 2015-present